Title | Height, Obesity, and the Risk of -Defined Prostate Cancer. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Heiden MGVander, Fiorentino M, Giovannucci EL, Loda M, Mucci LA |
Journal | Cancer Epidemiol Biomarkers Prev |
Volume | 27 |
Issue | 2 |
Pagination | 193-200 |
Date Published | 2018 02 |
ISSN | 1538-7755 |
Keywords | Adult, Aged, Body Height, Body Mass Index, Body Weight, Follow-Up Studies, Humans, Male, Middle Aged, Obesity, Oncogene Proteins, Fusion, Prospective Studies, Prostatic Neoplasms, Risk Factors, Transcriptional Regulator ERG |
Abstract | The largest molecular subtype of primary prostate cancer is defined by the gene fusion. Few studies, however, have investigated etiologic differences by status. Because the fusion is hormone-regulated and a man's hormonal milieu varies by height and obesity status, we hypothesized that both may be differentially associated with risk of -defined disease. Our study included 49,372 men from the prospective Health Professionals Follow-up Study. Participants reported height and weight at baseline in 1986 and updated weight biennially thereafter through 2009. Tumor ERG protein expression (a marker) was immunohistochemically assessed. We used multivariable competing risks models to calculate HRs and 95% confidence intervals (CIs) for the risk of ERG-positive and ERG-negative prostate cancer. During 23 years of follow-up, we identified 5,847 incident prostate cancers, among which 913 were ERG-assayed. Taller height was associated with an increased risk of ERG-positive disease only [per 5 inches HR 1.24; 95% confidence interval (CI), 1.03-1.50; = 0.07]. Higher body mass index (BMI) at baseline (per 5 kg/m HR 0.75; 95% CI, 0.61-0.91; = 0.02) and updated BMI over time (per 5 kg/m HR 0.86; 95% CI, 0.74-1.00; = 0.07) were associated with a reduced risk of ERG-positive disease only. Our results indicate that anthropometrics may be uniquely associated with -positive prostate cancer; taller height may be associated with greater risk, whereas obesity may be associated with lower risk. Our study provides strong rationale for further investigations of other prostate cancer risk factors that may be distinctly associated with subtypes. . |
DOI | 10.1158/1055-9965.EPI-17-0547 |
Alternate Journal | Cancer Epidemiol Biomarkers Prev |
PubMed ID | 29167279 |
PubMed Central ID | PMC5809280 |
Grant List | P50 CA090381 / CA / NCI NIH HHS / United States P01 CA087969 / CA / NCI NIH HHS / United States R25 CA112355 / CA / NCI NIH HHS / United States U01 CA167552 / CA / NCI NIH HHS / United States R01 CA131945 / CA / NCI NIH HHS / United States UM1 CA186107 / CA / NCI NIH HHS / United States T32 CA009001 / CA / NCI NIH HHS / United States R01 CA136578 / CA / NCI NIH HHS / United States / HHMI / Howard Hughes Medical Institute / United States |
Related Faculty:
Massimo Loda, M.D.